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D e s p i t e advances in v n v e n t i o n a l therapy, many lives c o n t i n u e to be lost to common forms of B - c e l l 
Cancers, including l e u k m i a s , lymphomas and multiple m y e l o m a . We p r o p o s e a novel approach to therapy 
of such Cancers using zontrolled expression of a diphtheria toxin gene (DT-A) to kill malignant cells. We 
have p r e v i o u s l y demoistrated s e l e c t i v e killing of various cell types, in vitro and in vivo, by cell-specific, 
transcriptionally contolled expression of this gene, Organ-specific a b l a t i o n in otherwise healthy 
t r a n s g e n i c m i c e has cmvincingly demonstrated the e x q u i s i t e specificity a c h i e v a b l e by this t e c h n i q u e 1 5 . 
I n t h e studies nov described, DT-A was delivered in vitro and in vivo using a novel gene delivery 
System employing DN/ physically attached to the exterior of adenovirus. After demonstrating the efficacy 
of gene delivery to Eptein-Barr virus transformed h u m a n B - c e l l s in vitro, in vivo work was performed 
using a SCID mouse nodel for B - c e l l lymphoma, in which p r o t e c t i o n against tumor was observed. The 
concepts of tissue-regüated toxin gene therapy, and this n o v e l adenovirus gene delivery System are 
discussed. 
INTRODUCTION 
Conventional Cancer teatment is hampered by 
the narrow therapeitic window of many 
antineoplastic agents. Since most chemotherapy 
attacks DNA syntheiis, effective therapy is 
severely limited by toxcity in normal replicating 
cell populations such is bone marrow and gut6. 
Restriction of the toxfe effects of chemotherapy 
Address reprint requests toDr. TylerJ. Curiel, Box B - 1 6 8 , 
D i v i s i o n of Infectious Dvease, University of Colorado 
H e a l t h Sciences Center, Demer, CO 8 0 2 6 2 
to malignant, rather than normal cells would be 
a great advance over therapies currently 
available. A convenient model for the study of 
cell-specific gene expression is represented by 
the B-cell malignancies. Regulatory nuclear 
proteins unique to B-cells bind transcriptional 
Promoter and enhancer sequences associated with 
the rearranged immunoglobulin (Ig) heavy and 
light chain coding sequences, leading to 
transcription of mRNA for the various Ig 
isotypes7. However, this unique series of events 
has never been specifically exploited as a means 
of therapy for lymphomas, leukemias, or 
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myeloma. 
Despite conventional chemotherapy, 30 to 
60% of patients with non-Hodgkin's lymphomas 
and more than 90% of myeloma patients relapse 
and succumb to their disease8. Infection with the 
Human Immunodeficiency virus (HIV) is 
currently associated with a large upsurge in 
B-cell lymphomas associated with Epstein-Barr 
virus (EBV) infection. This type of neoplasm is 
also seen in other settings associated with 
defective cell-mediated immunity. These tumors 
are likewise difficult to treat and often fatal9"10. 
Clinical use of natural toxins to kill tumor 
cells includes phase I/II trials in colon and breast 
Cancers, melanoma, and B-cell malignancies such 
as chronic lymphocytic leukemia and 
non-Hodgkin's lymphomas and T-cell 
leukemias11"13. As an alternative means of 
exploiting a natural toxin for tumor cell killing, 
we have suggested the use of diphtheria toxin A 
chain (DT-A) gene as the therapeutic agent. We 
first demonstrated that cells could be induced to 
"commit suicide" by expressing D T - A , and that 
such activity could be enhanced in a specific cell 
type14"15. We subsequently developed Ig-regulated 
DT-A expression constructs effecting high level 
DT-A expression in murine and human B-cells, 
with little expression in non-B-cells16"17, making 
them candidates as agents for B-cell-specific 
gene therapy. 
In regard to gene delivery Systems we 
demonstrated that addition of adenovirus to 
transfections using DNA/transferrin-polylysine 
complexes greatly enhanced the expression of 
heterologous DNA 1 8 . Next, we showed that if the 
DNA were physically linked to the adenovirus, 
heterologous gene expression was augmented by 
several Orders of magnitude over level s achieved 
using unbound DNA. Strategies to link DNA to 
adenovirus include biotinylated adenovirus 
coupled to DNA/streptavidin-polylysine, 
biotinylated adenovirus coupled to anti-biotin 
antibody-polylysine/DNA, and anti-adenovirus 
antibody bridges18 2 0 . 
This liganded adenovirus approach affords 
high-level heterologous gene expression in up to 
67% of EBV transformed human B-cells 
(B-LCL) in v i t r o , for up to 17 days20. 
Anti-human Ig conjugates (which bind to the 
surface Ig of B-cells) induced up to three times 
more reporter gene expression in B-LCL than 
that induced when transferrin-polylysine or 
polylysine were used20. 
Encouraged by these in v i t r o results, we used 
these conjugates to assess this novel adenovirus 
System for delivery of Ig-regulated DT-A to 
B-LCL in vivo in a SCID mouse model. SCID 
mice injected with B-LCL develop tumor ascites, 
and limited metastases21. By increasing the tumor 
cell inoculum from the order of 106 cells 
previously reported, to 107 cells, we were able to 
reproduce widely metastatic tumors in SCID 
mice. These tumors share a number of 
similarities with EBV-associated human 
immunoblastic lymphomas22"23. Treatment of 
these tumors using an Ig-regulated DT-A 
construct delivered by this adenovirus System 
apparently protected SCID mice from a lethal 
tumor challenge in the Single such experiment 
performed to date. 
METHODS 
Coryugate Synthesis 
Biotinylated adenovirus dl312 and 
streptavidin-polylysine conjugates were all 
prepared as described24. Biotinylation of 
adenovirus does not significantly affect viral titer 
(Wagner et a l , unpublished observations). 
Anti-human Ig-conjugates were prepared by 
conjugation through disulfide bridges after 
m o d i f i c a t i o n w i t h s u c c i n i m i d y l 
3-(2-pyridyldithio)propionate (SPDP; Pharmacia, 
Uppsala, Sweden) using goat anti-human Ig 
(Southern Biotechnology Associates, Inc., 
Birmingham, AL) and poly(L)lysine (with an 
average chain length of 300 monomers) at a 
molar ratio of 1:2 in analogous fashion as 
described25. Before use, antibodies were 
subjected to gel filtration (Sephadex G25; 150 
mM NaCl, 20 mM HEPES buffer, pH 7.3). Ig 
conjugates prepared in this fashion are 
uncontaminated by free Ig or free components 
(our unpublished observations). UV-psoralen 
inactivation of virus was performed as 
described18. 
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Flgure 1. Schematic representation of binary and ternary adenovirus-DNA-Iigand complexes. 
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4 * 
Adenovirus-DNA- Adenovirus - DNA -
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Complex Formation particles) in 50 \ i \ HBS (20 mM HEPES, pH 7.3 
and 150 mM NaCl) was mixed with 800 ng 
Binary DNA complexes were prepared as streptavidin-polylysine in 100 \ i \ HBS. After a 
follows: biotinylated adenovirus d!312 (3 x 1010 30 minute incubation at room temperature, a 
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Solution of 12 \ig plasmid DNA in 200 \il HBS 
was added, and after an additional 30 minute 
incubation at room temperature, a Solution of 5.1 
\ig poly(L)lysine (average chain length 450 
amino acids) in 150 \il HBS was added. A 
schematic of the final ligands is depicted in 
Figure 1. 
I n vitro transfections 
DNA complex Solutions were added to 3 x 105 
to 1 x 106 EBV-transformed B-cells (B-LCL) in 
24-well plates in 1 ml of RPMI-1640 plus 2% 
FCS. After 2 hours, 1 ml of RPMI-1640 plus 
20% FCS was added. Further cell culture 
procedures were as described42. 
Plasmids 
pRSVß-gal26, pCMVL 2 7 , pRSVL 2 8, have been 
previously described. pTHA81 is an Ig-regulated 
DT-A expression plasmid containing an Ig kappa 
Promoter and intragenic sequences, which confer 
efficient DT-A expression in murine B-cells17. 
The corresponding control plasmid pTHA7lADT 
contains a DT-A frameshift mutation. 
Cell lines 
B-LCL were made as described29. Briefly, 
peripheral blood mononuclear cells were isolated 
by Ficoll-Hypaque density centrifugation, and 
incubated with supernatant from the EBV 
producer cell line B95-8. Resultant B-LCL were 
maintained in RPMI-1640 (Gibco, Grand Island, 
NY) supplemented with 10-15% heat-inactivated 
fetal calf serum (Fisher, Pittsburgh, PA), 
glutamine 2 mM, Hepes buffer 10 mM, penicillin 
50 U/ml and streptomycin 50 ng/ml. Cells were 
diluted with fresh medium the day prior to 
animal inoculation to obtain exponential growth 
at the time of challenge. For the animal work 
described, the B-LCL line D N 2 0 was used. 
Assays for reporter gene expression 
Assays for luciferase 2 7 (lue) and 
ß-galactosidase30 (ß-gal) activity were performed 
as described. The lue inhibition co-transfection 
assay was performed as described16 except that 
the lue reporter was assayed on day 3 following 
transfection, as we had previously shown this to 
be the day of maximal reporter gene 
expression20. In addition, to aecount for the 
potentially toxic effects of biotinylated 
adenovirus or chimeric proteins, for assays in 
which less than 6 \ig DNA was used, 
biotinylated adenovirus (free of DNA) was added 
in excess of that needed to deliver DNA to make 
all transfections contain the identical amount of 
virus and chimeric proteins. 
SCID mouse experiments 
SCID mice of either sex, 6 to 10 weeks old were 
purchased from Taconic. Animals were housed 
in microisolator cages with three to five animals 
per cage, and fed sterile water and autoclaved 
food pellets ad l i b i t u m . Prophylactic antibiotics 
were not used. Animals were inoculated with 3 
x 107 B-LCL by intraperitoneal injection. 12 \ig 
plasmid DNA was conjugated to adenovirus 
using polylysine in the final incubation and 
injected into the animals i.p. immediately after 
tumor challenge, on the side contralateral from 
the tumor inoculation. Separate syringes weie 
used for cell and DNA injections, and no mixing 
of cells or gene transfer reagents occurred ex 
vivo. UV-psoralen inactivated virus was used for 
all animal work. All dying animals were 
necropsied and tissues were examined using 
Standard histologic techniques to assess for tbe 
presence of tumor. This protoeol was approved 
by the Animal Care Committee of the University 
of Colorado Health Sciences Center. 
RESULTS 
Non-specific toxicity of virus/DNA conjugates 
in cell culture 
We first tested for non-specific toxic effects of 
adenovirus/DNA conjugates on B-LCL using 
pRSVLuc, a plasmid known not to be toxic for 
these cells. Transfection of B-LCL with 
conjugates made from replication defective 
adenovirus dl312 rapidly resulted in death of the 
cell culture. Conjugates made from 








F l g u r e 2 . U v 
P s o r a l e n - i n a c t i v a t e d 
adenovirus used in the 
production of DNA conjugates 
did not affect the growth of 
transduced B-LCL. Micrograms 
refer to the quantity of 
transduced pRSVLuc. The 
solid Squares with the caption 
"8 \LQ dl312" refer to 
conjugates delivered with 
replication-defective, but not 
UV-psoralen inactivated 
adenovirus. 
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UV-psoraleninactivated adenovirus showed no 
significant toxicity to cell culture using up to 8 
(ig total DNA (Fig. 2). Thus, the adenovirus 
itself, when inactivated and the corresponding 
chimeric proteins and DNA were not themselves 
toxic to B-LCL in the dose ränge of 2 to 8 \xg 
DNA. Unless noted otherwise, only UV-psoralen 
inactivated virus was used further in the 
formation of conjugates for the work reported 
here. 
Specific toxicity of pTHA81 for B-LCL 
600 ng of pTHA81 (Ig-regulated, DT-A 
encoding) was sufficient to effect 95% reduction 
in lue expression in the co-transfection assay 
(Fig. 3). By contrast, pTHA7lADT effected no 
detectable lue inhibition at a dose of up to 2 \ig 
DNA, although at higher doses, some inhibition 
was observed (Fig. 2, and data not shown). The 
toxicity at higher doses likely relates to the 
non-speeifie toxicity of adenovirus proteins, even 
when heat-killed (our unpublished data), 
Therefore, as expected, the plasmid encoding the 
functional DT-A gene showed significant toxicity 
for B-LCL even when low doses were used in 
this co-transfection assay. 
Adenovirus/DNA conjugates mediate gene 
transfer in vivo 
We had previously shown that this adenovirus 
System delivered a ß-gal reporter gene to B-LCL 
in v i v o 2 0 . For that work, we did not assess for 
reporter gene expression in mouse tissues. To 
extend those observations, two tumor-bearing 
animals were inoculated with 12 \ig of ß-gal 
reporter gene as described20 using an 
adenovirus-polylysine conjugate. ß-gal activity 
was detected in peritoneal serosa, spieen cells 
and liver, but not in control animals which were 
not inoculated with adenovirus conjugates (not 
shown). High background activity precluded 
adequate assessment of Fallopian tubes and 
kidneys. 














6»xg Figure 3. pTHA81 delivered by 
adenovirus/DNA/polylysine 
con juga tes spec i f i ca l l y 
inhibited luciferase expresäon 
of doubly transduced B-LCL. 
See materials and methods for 
details. Control maximum lue 
expression in untransduced 
ce l ls was 8800 l ight 
units/approximately 105 cell 
equivalents. Micrograms refers 




Effect of pTHA81 treatment on survival of 
mice bearing B-LCL tumors 
Five SCID mice were inoculated i.p. with 1 x 
107 B-LCL followed immediately by 12 \ig 
pTHA81. Five control mice were inoculated with 
B-LCL and treated with the control plasmid 
pTHA7lA DT in identical fashion. All dying 
animals were necropsied. The four control mice, 
and the pTHA81 treated mouse that died on day 
70 had widely metastatic tumor involving 
peritoneal cavity, liver, spieen, lymph nodes and 
other organs (not shown). The pTHA81 treated 
mouse that died on day 230 had no tumor 
detected by Standard histolcgic techniques, 
although more sensetive detection methods such 
as Polymerase chain reaction were not 
performed. pTHA81-treated animals had 
apparently longer survival than controls (Fig. 4), 
but Statistical analysis was not performed owing 
to the small number of animals involved. 
DISCUSSION 
We have previously demonstrated the feasibility 
of delivering foreign genes to human B-cell 
tumors using a novel adenovirus System20. We 
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now extend these observations to demonstrate 
that this System also mediates in v i t r o and in 
vivo delivery of an Ig-regulated DT-A expression 
construet to human B-cell tumors which is toxic 
to them. The conjugates (made with UV-psoralen 
inactivated virus) were found to be non-toxic for 
SCID mice as well, demonstrating that this 
model will be useful for further studies. 
Conjugates made from non-inactivated virus 
likewise were not harmful to SCID mice at doses 
of up to 100 jig DNA, corresponding to 3 x 1011 
viral particles (not shown). 
The ability to deliver genes in v i v o by 
intravenous injection with this System has not yet 
been unequivocally demonstrated, owing to 
inactivation of the conjugates in blood 
(unpublished observations). Nontheless, this 
delivery System may be applicable to non-blood 
compartments such as the peritoneal cavity, 
bladder epithelium or the central nervous System 
in its present form. Our finding of ß-gal reporter 
gene expression in distant organs (spieen and 
liver) following i.p. inoculation was unexpected, 
and may relate to diffusion of complexes in the 
peritoneal fluid or to ß-gal expression from 
transduced B-LCL that had migrated to those 
areas. ß-gal expression in these tissues owing to 
Flgure 4. pTHA81 delivered by 
adenovirus/DNA/polylysine 
conjugates to B-LCL bearing 
SCID mice apparently afforded 
a survival advantage. n = 5 
for each group of animals 
tested. 
0 50 100 150 200 250 
days after tumor challenge 
small amounts of complex surviving in blood is 
unlikely, based on our prior experience with 
intravenous delivery. Experiments to assess these 
possibilities are in progress. 
Many experiments in vivo in transgenic 
animals have clearly demonstrated that sufficient 
regulation of toxin gene expression may be 
achieved to produce animals with foreign gene 
expression only in targeted tissues even though 
all cells of the transgenic animal are transduced. 
We have also previously demonstrated16'17'55"58 the 
exquisite specificity of regulated DT-A 
expression Systems in v i t r o . Due to this high 
level of specificity, it is possible to exploit the 
efficiency of relatively non-specific gene delivery 
pathways, including the transferrin receptor, 
polycationic lipids, and the charge-dependent 
polylysine ligand used here. 
These experiments were performed with a 
B-cell-specific plasmid, but a B-cell-specific 
ligand for cell targeted delivery was not used. 
Using these non-tissue specific ligands, we 
demonstrated ß-gal reporter gene expression in 
numerous mouse tissues. The fact that 
tumor-bearing mice did not experience clinical 
or histologic signs of conjugate-associated 
toxicity suggests that the Ig regulation of DT-A 
expression must have been sufficiently stringent 
to have afforded an acceptable therapeutic index. 
These data therefore further confirm the potential 
advantage of a genetically controlled toxin 
expression system. We have already 
demonstrated that anti-immunoglobulin-
polylysine ligands efficiently mediate 
heterologous gene delivery to B-LCL in v i t r o 2 0 . 
The B-cell specificity of these, and other ligands, 
and means to decrease non-specific interactions 
of the polylysine, adenovirus and other 
components of the conjugates are in progress. 
Nonetheless,we acknowledge that B-cell specific 
complexes will bind to normal as well as 
malignant B-cells, thus potentially diluting their 
therapeutic effect. 
Many different non-viral Systems to accomplish 
gene transfer have also been developed, 
including CaP04 co-precipitation31, liposomes32, 
and direct DNA injection33. These methods are 
ultimately membrane perturbing, and thus may 
be associated with significant cytotoxicity. In 
addition, because most non-viral vectors do not 
possess a specific mechanism to facilitate gene 
transfer events distal to cell membrane 
transition, they may be extremely inefficient. In 
v i v o , gene transfer efficiencies with these agents 
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may be further compromised by lack of 
cell-specific tropism and clearance by 
reticuloendothelial mechanisms34. 
Design of recombinant viral vectors may be 
limited if tissue-specific expression is desired or 
if the introduced foreign gene requires regulation 
of expression. The obligatory co-introduction of 
elements of the genome of the parent virus poses 
significant safety hazards. To circumvent these 
limitations, methods have been developed to 
deliver DNA by the receptor-mediated 
endocytosis pathway35 4 8 , the merits of which 
have been described elsewhere49"50. 
Adenovirus was chosen as the "backbone" for 
our conjugates for several reasons. The entry 
pathway of adenovirus is analogous to that of the 
conjugate vector in certain respects. Like the 
molecular conjugate vector, the adenovirus has 
an efficient internalization mechanism via a 
cellular internalization pathway. Unlike the 
molecular conjugate vector, however, after entry 
the adenovirus possesses a specific mechanism to 
escape from the cell vesicle System and thus 
avoid lysosomal degradation. 
Despite the extreme toxicity of diphtheria and 
ricin toxin, the genes encoding the A-chains of 
these toxins can be placed under specific 
transcriptional regulation with sufficient 
stringency to ablate specific tissues (such as 
exocrine pancreas, eye lens or pituitary 
somatotropes) during development without other 
adverse effects on the transgenic animals1"5. We 
chose to deliver a regulated toxin gene using our 
liganded adenovirus delivery System. Others have 
exploited similar strategies in the development of 
chimeric proteins delivering a toxin by means of 
the specificity of the ccnjugated receptor12,13. 
While targeted toxin genes may be used in 
therapy of various forms of Cancer, leukemias 
(especially of lymphoid cells), lymphomas and 
multiple myeloma represent particularly 
appropriate diseases for developing and applying 
such a therapeutic approach for reasons stated 
above. Since transient expression of small 
amounts of toxin would suffice to achieve cell 
death, tumor ablation may be more readily 
achievable than in most Systems in which 
long-term expression of substantial amounts of 
gene product is required51. For the present, our 
efforts are directed towards efficient ablation of 
any B-cells, rather than only malignant B-cells. 
This does not necessarily negate the therapeutic 
usefulness of this approach, bearing in mind that 
conventional chemotherapy is still less specific. 
Furthermore, in the unlikely event all B-cells 
were to be ablated by this method, one would 
expect regrowth from bone marrow progenitor 
cells in a few weeks7. Finally, it is unlikely that 
any one therapeutic approach to the treatment of 
these Cancers will be effective. Thus, if these 
therapies serve to decrease tumor mass, they may 
be combined with other therapies to afford an 
outcome superior to the use of either alone. 
It is important to point out both the potential 
advantages and problems associated with this 
type of gene therapy. While targeting 
tissue-specific gene expression is a radical 
departure from most previous methods, 
tissue-specific targeting is far from 
cancer-specific. However, it is also true that 
many tissues are not required for survival, and 
that chemotherapy is also not cancer-specific. 
Furthermore, targeting Ig synthesis should 
provide a therapeutic window which might 
actually spare normal stem cells capable of 
reconstituting the immune system, and would 
potentially be less toxic than the highly 
immunosuppressive combination chemotherapy 
regimens now employed. Other possible 
disadvantages include resistance to therapy by 
down-regulation of conjugate receptors on cell 
surfaces, antibody formation against conjugates 
and resistance to the effects of DT-A (such as 
development of mutant elongation factor 2). 
Some of these disadvantages are shared with 
monoclonal antibodies and chemotherapy. 
Because it is likely that patients treated with 
adenovirus conjugates will develop neutralizing 
antibodies leading to rapid clearance of viral 
particles, virus particles may be engineered with 
sufficiently different capsid proteins to avoid 
neutralization during repeated treatments. 
Nonetheless, in a study of application of 
recombinant adenoviruses to respiratory 
epithelium, efficient gene delivery was 
accomplished despite the development of 
high-titer local anti-adenovirus IgA antibody52. 
The multiple adenovirus strain approach has been 
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used successfully in a primate model53. 
Furthermore, compared with other gene therapy 
efforts which will generally require long-term, 
stable expression of large amounts of protein, 
our approach theoretically requires only transient 
expression of small amounts of protein to be 
successful. Thus, the number of required 
treatments may be minimized. Moreover, the 
specific targeting of protein synthesis by DT-A 
already abrogates the known gene-mediated 
multidrug resistance which develops rapidly in 
B-cell neoplasms54. 
In summary, these studies demonstrate the 
efficacy of B-LCL growth inhibition in vitro, and 
apparently in vivo as well using an Ig-regulated 
DT-A gene delivered by a novel adenovirus 
System. Although these data suggest efficacy in 
an animal model, further work will be necessary 
to confirm these results, and to gain a clearer 
understanding of the mechanisms by which these 
conjugates afford protection. In addition, the 
conjugates are complex, with much potential for 
non-specific interactions which may ultimately 
hinder or possibly negate their use as 
cell-specific delivery agents. Nevertheless, we 
feel these experiments serve as tentative steps 
towards elucidation of clinically useful gene 
therapy strategies directed at B-cell (and possibly 
other) malignancies. Thus, toxin gene therapy for 
B-cell malignancies may ultimately be feasible. 
Further work will focus on the use of B-cell 
specific ligands, such as anti-immunoglobulin-
polylysine, and on the production of conjugates 
stable by intravenous injection. 
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